Physician profile
Wallace E Holland
NPI 1972501799
$4,399.01
in general payments reported to CMS, 2019-2025
38 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.84 · 2020: $51.36 · 2021: $202 · 2022: $343 · 2023: $591 · 2024: $1,613 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,642 · Long Term Medical Supply Or Device Loan: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,642.08 |
| Long Term Medical Supply Or Device Loan | $123.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $586.69 | 2023-2025 | |
| Novo Nordisk INC | $536.78 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $493.85 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $413.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $326.02 | 2022-2025 | Farxiga, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.92 | 2021-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $138.75 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $126.73 | 2019-2025 | Otezla, Repatha, Evenity |
| Baxter Healthcare | $123.96 | 2025 | Hillrom - Spot Vision Screener |
| Astellas Pharma US INC | $115.05 | 2024-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $111.39 | 2020-2024 | Xarelto, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.89 | 2024-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $99.13 | 2021-2025 | |
| Horizon Therapeutics Plc | $96.23 | 2022-2023 | Krystexxa |
| Pfizer INC. | $89.28 | 2024-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Holland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.